Last updated: 11/03/2018 20:45:56
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study.

Drug Use Investigation of VOTRIENT® Tablets (Investigation in Patients with Renal Cell Carcinoma)

GSK study ID
200281
See study documents
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Drug Use Investigation of VOTRIENT® Tablets (Investigation in Patients with Renal Cell Carcinoma)
Trial description: This investigation will be conducted to collect and assess information regarding the safety and effectiveness of pazopanib tablets in patients with renal cell carcinoma (RCC) in routine clinical practice.
VOTRIENT is a registered trademark of the GSK Group of Companies.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Overall survival

Timeframe: 1 year

Occurrence of adverse drug reactions (ADRs) and infections

Timeframe: 1 year

Occurrence of ADRs when dose is increased following dose reduction

Timeframe: 1 year

Response rate

Timeframe: 1 year

Secondary outcomes:
Not applicable
Interventions:
  • Drug: Pazopanib
    • Enrollment:
    150
    Primary completion date:
    Not applicable
    Observational study model:
    Case-Only
    Time perspective:
    Prospective
    Clinical publications:
    Not applicable
    Medical condition
    Carcinoma, Renal Cell
    Product
    pazopanib
    Collaborators
    Not applicable
    Study date(s)
    August 2014 to February 2018
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    Not applicable
    Accepts healthy volunteers
    none
    • Patients who were diagnosed as having unresectable or metastatic RCC
    • Patients who are treated with pazopanib for the first time
    • None
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Patients who were diagnosed as having unresectable or metastatic RCC
    • Patients who are treated with pazopanib for the first time
    Exclusion criteria:
    • None

    Trial location(s)

    This study does not involve prospective enrollment of participants.

    Study documents

    Scientific result summary
    Available language(s): English
    Download document(s)

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    No longer a GSK study
    Actual primary completion date
    Not applicable
    Actual study completion date
    Not applicable

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website